Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, B-Cell 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Recurrence 1Potentially Resectable Locally Advanced Malignant Tumors of Biliary System 1Pancreatic Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Klatskin Tumor 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Fluorouracil 4Oxaliplatin 3Capecitabine 3toripalimab 2dehydroftorafur 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Leucovorin 2Biopsy 2tremelimumab 1trametinib 1tislelizumab 1temoporfin 1sacituzumab govitecan 1lenvatinib 1gemcitabine-oxaliplatin regimen 1durvalumab 1binimetinib 1Stents 1Sorafenib 1Radiosurgery 1Hydroxychloroquine 1Gemcitabine 1Erlotinib Hydrochloride 1Cisplatin 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Klatskin Tumor × gemcitabine-oxaliplatin regimen × Clear all
NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Peking University

Phase 2 Terminated
1 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡